Antibiotic-mediated bacteriome depletion in ApcMin/+ mice is associated with reduction in mucus-producing goblet cells and increased colorectal cancer progression

Cancer Medicine

Volumn 7, Issue 5, 2018, Pages 2003-2012

  Kaur, Kamaljeet ^a   Saxena, Arpit ^a   Debnath, Irina ^a   O'Brien, Jacqueline L ^b   Ajami, Nadim J ^b   Auchtung, Thomas A ^b   Petrosino, Joseph F ^b   Sougiannis, Alexander Jacques ^a   Depaep, Sarah ^a   Chumanevich, Alexander ^a   Gummadidala, Phani M ^a   Omebeyinje, Mayomi H ^a   Banerjee, Sourav ^c   Chatzistamou, Ioulia ^d   Chakraborty, Paramita ^a   Fayad, Raja ^a   Berger, Franklin G ^a   Carson, James A ^a   Chanda, Anindya ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c The Department of Mechanical Engineering   (United States)

^d UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Colorectal cancer; Goblet cells; Microbiome

Indexed keywords

NEOMYCIN; STREPTOMYCIN; VANCOMYCIN; ADENOMATOUS POLYPOSIS COLI PROTEIN, MOUSE; ANTIINFECTIVE AGENT; APC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL COUNT; COLON TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; ENTERITIS; ENTEROCOCCUS; FAMILIAL ADENOMATOUS POLYPOSIS; FECES ANALYSIS; GASTROINTESTINAL POLYPOSIS; GOBLET CELL; HISTOPATHOLOGY; INTESTINE FLORA; INTESTINE TISSUE; LONG TERM CARE; MOUSE; NONHUMAN; PEPTOCLOSTRIDIUM; PRIORITY JOURNAL; UREAPLASMA; ANIMAL; C57BL MOUSE; COLON; COLON POLYPOSIS; CYTOLOGY; DISEASE EXACERBATION; DISEASE MODEL; DRUG EFFECT; GENETICS; INTESTINE MUCOSA; MICROBIOLOGY; PATHOLOGY; TRANSGENIC MOUSE;

ADENOMATOUS POLYPOSIS COLI; ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ANTI-BACTERIAL AGENTS; COLON; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GASTROINTESTINAL MICROBIOME; GOBLET CELLS; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOMYCIN; STREPTOMYCIN; VANCOMYCIN;

EID: 85044952219     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.1460     Document Type: Article

References (73)

1. Sundin, J., L. Ohman, and M. Simren. 2017. Understanding the Gut microbiota in inflammatory and functional gastrointestinal diseases. Psychosom. Med. 79:857–867.
2. Rojo, D., C. Mendez-Garcia, B. A. Raczkowska, R. Bargiela, A. Moya, M. Ferrer, et al. 2017. Exploring the human microbiome from multiple perspectives: factors altering its composition and function. FEMS Microbiol. Rev. 41:453–478.
3. Tropini, C., K. A. Earle, K. C. Huang, and J. L. Sonnenburg. 2017. The Gut Microbiome: Connecting Spatial Organization to Function. Cell Host Microbe 21:433–442.
4. Bordalo Tonucci, L., K. M. Dos Santos, C. L. De Luces Fortes Ferreira, S. M. Ribeiro, L. L. De Oliveira, and H. S. Martino. 2017. Gut microbiota and probiotics: focus on diabetes mellitus. Crit. Rev. Food Sci. Nutr. 57:2296–2309.
5. Altuntas, Y., and A. Batman. 2017. Microbiota and metabolic syndrome. Turk. Kardiyol. Dern. Ars. 45:286–296.
6. Jiang, C., G. Li, P. Huang, Z. Liu, and B. Zhao. 2017. The Gut Microbiota and Alzheimer's Disease. J. Alzheimers Dis. 58:1–15.
7. Katz-Agranov, N., and G. Zandman-Goddard. 2017. The microbiome and systemic lupus erythematosus. Immunol. Res. 65:432–437.
8. Pevsner-Fischer, M., E. Blacher, E. Tatirovsky, I. Z. Ben-Dov, and E. Elinav. 2017. The gut microbiome and hypertension. Curr. Opin. Nephrol. Hypertens. 26:1–8.
9. Rieder, R., P. J. Wisniewski, B. L. Alderman, and S. C. Campbell. 2017. Microbes and mental health: a review. Brain Behav. Immun. 66:9–17.
10. Serino, M., S. Nicolas, M. S. Trabelsi, R. Burcelin, and V. Blasco-Baque. 2017. Young microbes for adult obesity. Pediatr. Obes. 12:e28–e32.
11. Signoretti, M., R. Roggiolani, C. Stornello, G. Delle Fave, and G. Capurso. 2017. Gut microbiota and pancreatic diseases. Minerva Gastroenterol. Dietol. 63:399–410.
12. Tang, W. H., T. Kitai, and S. L. Hazen. 2017. Gut Microbiota in Cardiovascular Health and Disease. Circ. Res. 120:1183–1196.
13. Vaiserman, A. M., A. K. Koliada, and F. Marotta. 2017. Gut microbiota: a player in aging and a target for anti-aging intervention. Ageing Res. Rev. 35:36–45.
14. Dzutsev, A., J. H. Badger, E. Perez-Chanona, S. Roy, R. Salcedo, C. K. Smith, et al. 2017. Microbes and Cancer. Annu. Rev. Immunol. 35:199–228.
15. Rajagopala, S. V., S. Vashee, L. M. Oldfield, Y. Suzuki, J. C. Venter, A. Telenti, et al. 2017. The human microbiome and cancer. Cancer Prev. Res. (Phila.) 10:226–234.
16. Gao, R., Z. Gao, L. Huang, and H. Qin. 2017. Gut microbiota and colorectal cancer. Eur. J. Clin. Microbiol. Infect. Dis. 36:757–769.
17. Siegel, R. L., K. D. Miller, S. A. Fedewa, D. J. Ahnen, R. G. Meester, A. Barzi, et al. 2017. Colorectal cancer statistics, 2017. CA Cancer J. Clin. 67:177–193.
18. Weisburger, J., B. S. Reddy, T. Narisawa, and E. Wynder. 1975. Germ-free status and colon tumor induction by N-methyl-N'-nitro-N-nitrosoguanidine. Proc. Soc. Exp. Biol. Med. 148:1119–1121.
19. Li, Y., P. Kundu, S. W. Seow, C. T. de Matos, L. Aronsson, K. C. Chin, et al. 2012. Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APCMin/+ mice. Carcinogenesis 33:1231–1238.
20. Hu, B., E. Elinav, S. Huber, T. Strowig, L. Hao, A. Hafemann, et al. 2013. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proc. Natl. Acad. Sci. U S A. 110:9862–9867.
21. Zackular, J. P., N. T. Baxter, K. D. Iverson, W. D. Sadler, J. F. Petrosino, G. Y. Chen, et al. 2013. The gut microbiome modulates colon tumorigenesis. MBio 4:e00692–13.
22. Sanapareddy, N., R. M. Legge, B. Jovov, A. McCoy, L. Burcal, F. Araujo-Perez, et al. 2012. Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. ISME J. 6:1858–1868.
23. Sobhani, I., J. Tap, F. Roudot-Thoraval, J. P. Roperch, S. Letulle, P. Langella, et al. 2011. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS ONE 6:e16393.
24. Wang, T., G. Cai, Y. Qiu, N. Fei, M. Zhang, X. Pang, et al. 2012. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 6:320–329.
25. Wu, N., X. Yang, R. Zhang, J. Li, X. Xiao, Y. Hu, et al. 2013. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb. Ecol. 66:462–470.
26. Wu, Y. J., C. T. Wu, X. B. Zhang, W. T. Ou, and P. Huang. 2012. Clinical study of different bowel preparations on changes of gut flora in patients undergoing colorectal resection. Zhonghua. Wei. Chang. Wai. Ke. Za. Zhi. 15:574–577.
27. Hicks, L. A., T. H. Jr Taylor, and R. J. U. S. Hunkler. 2013. outpatient antibiotic prescribing, 2010. N. Engl. J. Med. 368:1461–1462.
28. Lee, G. C., K. R. Reveles, R. T. Attridge, K. A. Lawson, I. A. Mansi, J. S. Lewis, et al. 2014. Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med. 12:96.
29. Marra, F., D. George, M. Chong, S. Sutherland, and D. M. Patrick. 2016. Antibiotic prescribing by dentists has increased: why? J. Am. Dent. Assoc. 147:320–327.
30. Tamma, P. D., and S. E. Cosgrove. 2016. Addressing the appropriateness of outpatient antibiotic prescribing in the United States: an important first step. JAMA 315:1839–1841.
31. Vaz, L. E., K. P. Kleinman, M. A. Raebel, J. D. Nordin, M. D. Lakoma, M. M. Dutta-Linn, et al. 2014. Recent trends in outpatient antibiotic use in children. Pediatrics 133:375–385.
32. Ponziani, F. R., F. Scaldaferri, V. Petito, F. P. Sterbini, S. Pecere, L. R. Lopetuso, et al. 2016. The role of antibiotics in gut microbiota modulation: the eubiotic effects of rifaximin. Dig. Dis. 34:269–278.
33. Puiman, P., B. Stoll, L. Molbak, A. de Bruijn, H. Schierbeek, M. Boye, et al. 2013. Modulation of the gut microbiota with antibiotic treatment suppresses whole body urea production in neonatal pigs. Am. J. Physiol. Gastrointest. Liver Physiol. 304:G300–G310.
34. Kerman, D. H., and A. R. Deshpande. 2014. Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management. Postgrad. Med. 126:7–19.
35. Rahmoune, H., N. Boutrid, M. Amrane, and B. Bioud. 2017. Antibiotics, intestinal dysbiosis and risk of celiac disease. Dig. Liver Dis. 49:106.
36. Cao, Y., K. Wu, R. Mehta, D. A. Drew, M. Song, P. Lochhead, et al. 2018. Long-term use of antibiotics and risk of colorectal adenoma. Gut 67:672–678.
37. Attur, M. G., R. N. Patel, P. D. Patel, S. B. Abramson, and A. R. Amin. 1999. Tetracycline up-regulates COX-2 expression and prostaglandin E2 production independent of its effect on nitric oxide. J. Immunol. 162:3160–3167.
38. Dixon, D. A., F. F. Blanco, A. Bruno, and P. Patrignani. 2013. Mechanistic aspects of COX-2 expression in colorectal neoplasia. Recent Results Cancer Res. 191:7–37.
39. Moser, A. R., H. C. Pitot, and W. F. Dove. 1990. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247:322–324.
40. Tong, Y., W. Yang, and H. P. Koeffler. 2011. Mouse models of colorectal cancer. Chin J. Cancer 30:450–462.
41. Oh, J. E., B. C. Kim, D. H. Chang, M. Kwon, S. Y. Lee, D. Kang, et al. 2016. Dysbiosis-induced IL-33 contributes to impaired antiviral immunity in the genital mucosa. Proc. Natl. Acad. Sci. U S A. 113:E762–E771.
42. Russell, S. L., M. J. Gold, M. Hartmann, B. P. Willing, L. Thorson, M. Wlodarska, et al. 2012. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep. 13:440–447.
43. Strzepa, A., M. Majewska-Szczepanik, P. Kowalczyk, D. Wozniak, S. Motyl, and M. Szczepanik. 2016. Oral treatment with enrofloxacin early in life promotes Th2-mediated immune response in mice. Pharmacol. Rep. 68:44–50.
44. Saxena, A., R. Fayad, K. Kaur, S. Truman, J. Greer, J. A. Carson, et al. 2017. Dietary selenium protects adiponectin knockout mice against chronic inflammation induced colon cancer. Cancer Biol. Ther. 18:257–267.
45. Saxena, A., A. Chumanevich, E. Fletcher, B. Larsen, K. Lattwein, K. Kaur, et al. 2012. Adiponectin deficiency: role in chronic inflammation induced colon cancer. Biochim. Biophys. Acta 1822:527–536.
46. Aagaard, K., J. Petrosino, W. Keitel, M. Watson, J. Katancik, N. Garcia, et al. 2013. The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters. FASEB J. 27:1012–1022.
47. Berry, D., C. Schwab, G. Milinovich, J. Reichert, K. B. Mahfoudh, T. Decker, et al. 2012. Phylotype-level 16S rRNA analysis reveals new bacterial indicators of health state in acute murine colitis. ISME J. 6:2091–2106.
48. Seedorf, H., S. Kittelmann, G. Henderson, and P. H. Janssen. 2014. RIM-DB: a taxonomic framework for community structure analysis of methanogenic archaea from the rumen and other intestinal environments. PeerJ 2:e494.
49. Caporaso, J. G., J. Kuczynski, J. Stombaugh, K. Bittinger, F. D. Bushman, E. K. Costello, et al. 2010. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7:335–336.
50. Haas, B. J., D. Gevers, A. M. Earl, M. Feldgarden, D. V. Ward, G. Giannoukos, et al. 2011. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res. 21:494–504.
51. McDonald, D., M. N. Price, J. Goodrich, E. P. Nawrocki, T. Z. DeSantis, A. Probst, et al. 2012. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 6:610–618.
52. Knights, D., J. Kuczynski, O. Koren, R. E. Ley, D. Field, R. Knight, et al. 2011. Supervised classification of microbiota mitigates mislabeling errors. ISME J. 5:570–573.
53. He, Q., X. Li, C. Liu, L. Su, Z. Xia, X. Li, et al. 2016. Dysbiosis of the fecal microbiota in the TNBS-induced Crohn's disease mouse model. Appl. Microbiol. Biotechnol. 100:4485–4494.
54. Jakobsson, H. E., A. M. Rodriguez-Pineiro, A. Schutte, A. Ermund, P. Boysen, M. Bemark, et al. 2015. The composition of the gut microbiota shapes the colon mucus barrier. EMBO Rep. 16:164–177.
55. Boursi, B., K. Haynes, R. Mamtani, and Y. X. Yang. 2015. Impact of antibiotic exposure on the risk of colorectal cancer. Pharmacoepidemiol. Drug Saf. 24:534–542.
56. Dik, V. K., M. G. van Oijen, H. M. Smeets, and P. D. Siersema. 2016. Frequent use of antibiotics is associated with colorectal cancer risk: results of a nested case-control study. Dig. Dis. Sci. 61:255–264.
57. Kilkkinen, A., H. Rissanen, T. Klaukka, E. Pukkala, M. Heliövaara, P. Huovinen, et al. 2008. Antibiotic use predicts an increased risk of cancer. Int. J. Cancer 123:2152–2155.
58. Wang, J. L., C. H. Chang, J. W. Lin, L. C. Wu, L. M. Chuang, and M. S. Lai. 2014. Infection, antibiotic therapy and risk of colorectal cancer: a nationwide nested case-control study in patients with Type 2 diabetes mellitus. Int. J. Cancer 135:956–967.
59. Cox, L. M., S. Yamanishi, J. Sohn, A. V. Alekseyenko, J. M. Leung, I. Cho, et al. 2014. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 158:705–721.
60. Boursi, B., R. Mamtani, K. Haynes, and Y. X. Yang. 2015. The effect of past antibiotic exposure on diabetes risk. Eur. J. Endocrinol. 172:639–648.
61. de Kort, S., A. A. M. Masclee, S. Sanduleanu, M. P. Weijenberg, M. P. van Herk-Sukel, N. J. Oldenhof, et al. 2017. Higher risk of colorectal cancer in patients with newly diagnosed diabetes mellitus before the age of colorectal cancer screening initiation. Sci. Rep. 7:46527.
62. Zhu, B., X. Wu, B. Wu, D. Pei, L. Zhang, and L. Wei. 2017. The relationship between diabetes and colorectal cancer prognosis: a meta-analysis based on the cohort studies. PLoS ONE 12:e0176068.
63. Boursi, B., R. Mamtani, K. Haynes, and Y. X. Yang. 2015. Recurrent antibiotic exposure may promote cancer formation–Another step in understanding the role of the human microbiota? Eur. J. Cancer 51:2655–2664.
64. Kaur, K., A. Saxena, B. Larsen, S. Truman, N. Biyani, E. Fletcher, et al. 2015. Mucus mediated protection against acute colitis in adiponectin deficient mice. J. Inflamm. (Lond.) 12:35.
65. Kaul, M., and D. S. Pilch. 2002. Thermodynamics of aminoglycoside-rRNA recognition: the binding of neomycin-class aminoglycosides to the A site of 16S rRNA. Biochemistry 41:7695–7706.
66. Waksman, S. A., and H. A. Lechevalier. 1949. Neomycin, a New Antibiotic Active against Streptomycin-Resistant Bacteria, including Tuberculosis Organisms. Science 109:305–307.
67. Small, P. M., and H. F. Chambers. 1990. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. 34:1227–1231.
68. Gonzalez, C., M. Rubio, J. Romero-Vivas, M. Gonzalez, and J. J. Picazo. 1999. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin. Infect. Dis. 29:1171–1177.
69. Van Bambeke, F. 2006. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr. Opin. Investig. Drugs 7:740–749.
70. Chakraborty, S. P., S. K. Sahu, S. K. Mahapatra, S. Santra, M. Bal, S. Roy, et al. 2010. Nanoconjugated vancomycin: new opportunities for the development of anti-VRSA agents. Nanotechnology 21:105103.
71. Stemp, G., S. Pascoe, and D. Gatehouse. 1989. In vitro and in vivo cytogenetic studies of three beta-lactam antibiotics (penicillin VK, ampicillin and carbenicillin). Mutagenesis 4:439–445.
72. Buret, A. G. 2010. Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin. Can. J. Vet. Res. 74:1–10.
73. Hamoya, T., S. Miyamoto, S. Tomono, G. Fujii, R. Nakanishi, M. Komiya, et al. 2017. Chemopreventive effects of a low-side-effect antibiotic drug, erythromycin, on mouse intestinal tumors. J. Clin. Biochem. Nutr. 60:199–207.